OBJECTIVE: To estimate the average loss in life expectancy (LE) due to bladder cancer (BC) in men and women in the USA. PATIENTS AND METHODS: Cancer records for 51,528 patients diagnosed with BC during 1988-1997 were obtained from the Surveillance, Epidemiology, and End Results database. Potential follow-up ranged from 10 to 20 years (median 14 years). Loss in median LE at BC diagnosis was computed as the difference between expected median survival and observed median survival. Expected survival was calculated using two methods: method 1 used age, sex, and race-specific LE in the general population, method 2 used the hazard of death from non-BC causes in patients with BC (to account for past exposures and treatment-related toxicities not present in the general population). RESULTS: During the study period, BC death occurred in 17% of men and 23% of women and non-BC death occurred in 53% of men and 47% of women. Using LE in the general population as the reference (method 1), loss in median LE at BC diagnosis was 3.9 years for men (33% of their potential remaining years of life) and 6.5 years for women (47% of their potential remaining years of life). Using non-BC-specific hazard as the reference (method 2), loss in median LE was 2.7 years for men (26% of their potential remaining years of life) and 4.1 years for women (36% of their potential remaining years of life). CONCLUSION: Compared with men, women loose more years of life and a greater fraction of their life expectancy to BC.
OBJECTIVE: To estimate the average loss in life expectancy (LE) due to bladder cancer (BC) in men and women in the USA. PATIENTS AND METHODS: Cancer records for 51,528 patients diagnosed with BC during 1988-1997 were obtained from the Surveillance, Epidemiology, and End Results database. Potential follow-up ranged from 10 to 20 years (median 14 years). Loss in median LE at BC diagnosis was computed as the difference between expected median survival and observed median survival. Expected survival was calculated using two methods: method 1 used age, sex, and race-specific LE in the general population, method 2 used the hazard of death from non-BC causes in patients with BC (to account for past exposures and treatment-related toxicities not present in the general population). RESULTS: During the study period, BC death occurred in 17% of men and 23% of women and non-BC death occurred in 53% of men and 47% of women. Using LE in the general population as the reference (method 1), loss in median LE at BC diagnosis was 3.9 years for men (33% of their potential remaining years of life) and 6.5 years for women (47% of their potential remaining years of life). Using non-BC-specific hazard as the reference (method 2), loss in median LE was 2.7 years for men (26% of their potential remaining years of life) and 4.1 years for women (36% of their potential remaining years of life). CONCLUSION: Compared with men, women loose more years of life and a greater fraction of their life expectancy to BC.
Authors: Edward M Messing; Catherine M Tangen; Seth P Lerner; Deepak M Sahasrabudhe; Theresa M Koppie; David P Wood; Philip C Mack; Robert S Svatek; Christopher P Evans; Khaled S Hafez; Daniel J Culkin; Timothy C Brand; Lawrence I Karsh; Jeffrey M Holzbeierlein; Shandra S Wilson; Guan Wu; Melissa Plets; Nicholas J Vogelzang; Ian M Thompson Journal: JAMA Date: 2018-05-08 Impact factor: 56.272
Authors: Feng Jin; Jose Thaiparambil; Sri Ramya Donepudi; Venkatrao Vantaku; Danthasinghe Waduge Badrajee Piyarathna; Suman Maity; Rashmi Krishnapuram; Vasanta Putluri; Franklin Gu; Preeti Purwaha; Salil Kumar Bhowmik; Chandrashekar R Ambati; Friedrich-Carl von Rundstedt; Florian Roghmann; Sebastian Berg; Joachim Noldus; Kimal Rajapakshe; Daniel Gödde; Stephan Roth; Stephan Störkel; Stephan Degener; George Michailidis; Benny Abraham Kaipparettu; Balasubramanyam Karanam; Martha K Terris; Shyam M Kavuri; Seth P Lerner; Farrah Kheradmand; Cristian Coarfa; Arun Sreekumar; Yair Lotan; Randa El-Zein; Nagireddy Putluri Journal: Cancer Prev Res (Phila) Date: 2017-08-29